Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Analysts at Bank of America

Investment analysts at Bank of America initiated coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research report issued on Monday, MarketBeat reports. The brokerage set a “buy” rating and a $47.00 price target on the specialty pharmaceutical company’s stock. Bank of America‘s target price indicates a potential upside of 79.66% from the company’s current price.

Other equities analysts have also issued research reports about the stock. Piper Sandler began coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, November 4th. They issued an “overweight” rating and a $47.00 target price for the company. Zacks Research cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 3rd. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Jefferies Financial Group began coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday, November 4th. They issued a “strong-buy” rating for the company. Finally, Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $67.00 to $87.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Supernus Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $60.20.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $26.16 on Monday. Supernus Pharmaceuticals has a 1-year low of $25.92 and a 1-year high of $42.81. The business’s fifty day moving average price is $41.02 and its two-hundred day moving average price is $46.81. The company has a market capitalization of $3.09 billion, a P/E ratio of 7.31, a PEG ratio of 0.49 and a beta of 0.84.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.14). The business had revenue of $208.60 million during the quarter, compared to the consensus estimate of $217.56 million. Supernus Pharmaceuticals had a negative return on equity of 418.04% and a net margin of 32.75%. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.80) EPS. On average, research analysts expect that Supernus Pharmaceuticals will post 2.85 earnings per share for the current fiscal year.

Institutional Trading of Supernus Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Mystic Asset Management Inc. bought a new position in Supernus Pharmaceuticals during the second quarter valued at about $1,181,000. Bank of America Corp DE acquired a new position in Supernus Pharmaceuticals during the second quarter worth about $28,887,000. BlackRock Inc. bought a new stake in Supernus Pharmaceuticals in the second quarter worth about $434,871,000. The Manufacturers Life Insurance Company bought a new stake in Supernus Pharmaceuticals in the second quarter worth about $1,298,000. Finally, Great Lakes Advisors LLC bought a new stake in Supernus Pharmaceuticals in the second quarter worth about $1,386,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. Its work spans neurology and psychiatry, including therapies for epilepsy, attention-deficit/hyperactivity disorder (ADHD), and Parkinson’s disease.

The company’s marketed products include Qelbree for ADHD; Oxtellar XR and Trokendi XR for epilepsy; and medicines for Parkinson’s disease, including Apokyn, Xadago, and Ongentys. Its portfolio also includes Gocovri, which is used to treat certain movement complications associated with Parkinson’s disease.

Founded in 2005 and headquartered in Rockville, Maryland, Supernus expanded its commercial portfolio through acquisitions, including its 2022 acquisition of Adamas Pharmaceuticals.